Table 1.

Characteristics of 160 patients with advanced cancers

CharacteristicTotal no. of patientsNo. of patients with BRAFV600 mutation in FFPE tumor (%)No. of patients with BRAFV600 mutation in plasma cfDNA (%)
All16062 (39)47 (29)
Sex
Male8835 (40)27 (31)
Female7227 (38)20 (28)
Race
Caucasian13055 (42)42 (32)
African American121 (8)1 (8)
Hispanic155 (33)3 (20)
Asian31 (33)1 (33)
FFPE tumor tissue origin
Primary tumor6320 (32)16 (25)
Metastatic tumor9742 (43)31 (32)
FFPE tumor tissue testing
PCR5126 (51)18 (35)
Sequenom MassARRAY225 (23)2 (9)
Targeted NGS8731 (36)27 (31)
Type of BRAF mutation
V600E16060 (38)43 (27)
V600K1602 (1)4 (3)
Disease
Colorectal cancer6215 (24)13 (21)
Melanoma3626 (72)19 (53)
Non–small cell lung cancer134 (31)3 (23)
Thyroid cancer108 (80)5 (50)
Breast cancer100 (0)1 (10)
Appendiceal cancer52 (40)2 (40)
Uterine cancer40 (0)0 (0)
Ovarian cancer42 (50)0 (0)
Erdheim–Chester disease32 (67)2 (67)
Head and neck cancer30 (0)0 (0)
Carcinoma of unknown primary21 (50)1 (50)
Pancreatic cancer20 (0)0 (0)
Cholangiocarcinoma11 (100)1 (100)
Adrenocortical cancer10 (0)0 (0)
Glioblastoma11 (100)0 (0)
Hepatocellular carcinoma10 (0)0 (0)
Carcinoid tumor10 (0)0 (0)
Duodenal cancer10 (0)0 (0)
  • Abbreviation: NGS, next-generation sequencing.